Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Active, not recruiting	Phase 2	2026-03-27		NCT02682641

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	6
Janssen-Cilag, S.A.	3

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hospital Clínic de Barcelona	Barcelona	Spain	25
Hospital Clínico de Valencia	Valencia	Spain	3
Hospital Costa del Sol	Marbella	Spain	3
Hospital de la Santa Creu i Sant Pau	Barcelona	Spain	4
Hospital General Universitario Santa Lucía	Cartagena	Spain	2
Hospital Universitario 12 de Octubre	Madrid	Spain	55
Hospital Universitario Clinico de Salamanca	Salamanca	Spain	1
Hospital Universitario de Burgos	Burgos	Spain	3
Hospital Universitario Fundación Alcorcón	Alcorcón	Spain	2
Hospital Universitario Mútua Terrassa	Terrassa	Spain	1
Hospital Universitario Ramon y Cajal	Madrid	Spain	3
Hospital Universitario Vall d'Hebron	Barcelona	Spain	1
Hospital Universitario Virgen del Rocio	Seville	Spain	2
Institut Català d'Oncologia	Barcelona	Spain	2
MD Anderson Cancer Center	Madrid	Spain	1